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LIST OF ABREVIATIONS USED 
 
ECM Extra cellular matrix 
DNA Deoxy ribo nucleic acid 
DM Diabetes mellitus 
HB-EGF Heparin binding EGF 
MMP Matrix Metalloproteinase 
CDK Cyclin dependent kinase 
TNF Tumour necrosis factor 
EGF Epidermal growth factor 
HGF Hepatocyte growth factor 
PDGF Platelet derived growth factor 
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INTRODUCTION 
• Diabetic wounds or ulcers are major complication of diabetes mellitus 
•  Diabetes is a metabolic disorder that impedes the normal steps of 
wound healing process 
• Major increase in morbidity in diabetic patients is due to macro and 
micro vascular complications including failure of wound healing process 
• Diabetes is the cause for more than 3/4th lower limb amputation 
• Increased glucose in the tissue precipitates infection 
• Increased glycosylated tissue protein decreases the oxygen utilization 
• Epidermal growth factor will stimulates cell growth,proliferation and 
differentiation by binding to its receptor EGFR 
• It acts on epithelial cells and fibroblasts promoting restoration of 
damaged epithelium 
•  Current evidence suggests that application of human recombinant  EGF 
in addition to standard treatment is able to achieve both partial and 
complete healing and to prevent foot amputations.  
• It also enhances the wound healing in diabetic wounds 
• Its efficacy has been tested at various concentrations and by various 
administration routes (topical application and intralesional injection).   
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AIMS AND OBJECTIVE OF STUDY 
The aim of this study is to establish whether topical application of 
human epidermal growth factor enhance wound healing better than 
conventional povidone-iodine dressing in diabetic wounds  in Government 
Stanley Hospital, Chennai -1 
 
 
 
 
 
 
 
 
 
10 
 
REVIEW OF LITERATURE 
History of Wound Healing 
The earliest accounts of wound healing date back to about 2000 B.C., when the 
Sumerians employed two modes of treatment: a spiritual method consisting of 
incantations and a physical method of applying poultice-like materials to the 
wound.  
The Egyptians were the first to differentiate between infected and diseased 
wounds compared to noninfected wounds. 
 The 1650 B.C. Edwin Smith Surgical Papyrus, a copy of a much older 
document, describes at least 48 different types of wounds. 
 A later document (Ebers Papyrus, 1550 B.C.) relates the use of concoctions 
containing honey (antibacterial properties), lint (absorbent properties), and 
grease (barrier) for treating wounds. These same properties are still considered 
essential in contemporary daily wound management. 
The Greeks, equipped with the knowledge bequeathed by the Egyptians, went 
even further and classified wounds as acute or chronic in nature. 
 Galen of Pergamum (120–201 A.D.), appointed as the doctor to the Roman 
gladiators, had an enormous number of wounds to deal with after gladiatorial 
combats. He emphasized the importance of maintaining a moist environment to 
ensure adequate healing.  
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It took almost 19 centuries for this important concept to be proven 
scientifically, when it was shown that the epithelialization rate increases by 
50% in a moist wound environment when compared to a dry wound 
environment. 
The next major stride in the history of wound healing was the discovery of 
antiseptics and their importance in reducing wound infections. 
 Ignaz Philipp Semmelweis, a Hungarian obstetrician (1818–1865), noted that 
the incidence of puerperal fever was much lower if medical students, after 
cadaver-dissection class and before attending childbirth, washed their hands 
with soap and hypochlorite. 
 Louis Pasteur (1822–1895) was instrumental in dispelling the theory of 
spontaneous generation of germs and proving that germs were always 
introduced into the wound from the environment.  
Joseph Lister probably made one of the most significant contributions to 
wound healing. On a visit to Glasgow, Scotland, Lister noted that some areas of 
the city's sewer system were less murky than the rest. He discovered that the 
water from pipes that were dumping waste containing carbolic acid (phenol) 
was clear. In 1865, Lister began soaking his instruments in phenol and spraying 
the operating rooms, reducing the mortality rates from 50 to 15%. This practice 
led to the suspension of Lister, although subsequent confirmation of his results 
paved the way for his triumphant return to Edinburgh. 
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After attending an impressive lecture by Lister in 1876, Robert Wood Johnson 
left the meeting and began 10 years of research that would ultimately result in 
the production of an antiseptic dressing in the form of cotton gauze 
impregnated with iodoform. Since then, several other materials have been used 
to impregnate cotton gauze to achieve antisepsis. 
Polymeric dressings were developed in the 1960s and 1970s. These polymeric 
dressings can be custom made to specific parameters, such as permeability to 
gases (occlusive vs. semiocclusive), varying degrees of absorbency, and 
different physical forms. Due to the ability to customize, the available range of 
materials that aid in wound care has grown exponentially to include an ever-
expanding variety. Currently, the practice of wound healing encompasses 
manipulation and/or use of, among others, inflammatory cytokines, growth 
factors, and bioengineered tissue. It is the combination of all these modalities 
that enables optimal wound healing. 
Classification of Wounds 
Wounds are classified as either acute or chronic. Acute wounds heal in a 
predictable manner and time frame. The process occurs with few, if any, 
complications, and the end result is a well-healed wound.  
Surgical wounds can heal in several ways. An incised wound that is clean and 
closed by sutures is said to heal by primary intention. Often, because of 
bacterial contamination or tissue loss, a wound will be left open to heal by 
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granulation tissue formation and contraction; this constitutes healing by 
secondary intention.  
Delayed primary closure, or healing by tertiary intention, represents a 
combination of the first two, consisting of the placement of sutures, allowing 
the wound to stay open for a few days, and the subsequent closure of the 
sutures. 
Acute Wounds 
The healing spectrum of acute wounds is broad . In examining the 
acquisition of mechanical integrity and strength during healing, the normal 
process is characterized by a constant and continual increase that reaches a 
plateau at some point postinjury. 
 Wounds with delayed healing are characterized by decreased wound-
breaking strength in comparison to wounds that heal at a normal rate; however, 
they eventually achieve the same integrity and strength as wounds that heal 
normally. Conditions such as nutritional deficiencies, infections, or severe 
trauma cause delayed healing, which reverts to normal with correction of the 
underlying pathophysiology.  
Impaired healing is characterized by a failure to achieve mechanical 
strength equivalent to normally healed wounds. Patients with compromised 
immune systems, such as those with diabetes, chronic steroid usage, or tissues 
damaged by radiotherapy, are prone to this type of impaired healing 
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Chronic Wounds 
Chronic wounds are defined as wounds that have failed to proceed through the 
orderly process that produces satisfactory anatomic and functional integrity or 
that have proceeded through the repair process without producing an adequate 
anatomic and functional result. The majority of wounds that have not healed in 
3 months are considered chronic.  
Skin ulcers, which usually occur in traumatized or vascularly compromised soft 
tissue, are also considered chronic in nature, and proportionately are the major 
component of chronic wounds.  
Repeated trauma, poor perfusion or oxygenation, and/or excessive 
inflammation contribute to the causation and the perpetuation of the chronicity 
of wounds. 
Unresponsiveness to normal regulatory signals also has been implicated as a 
predictive factor of chronic wounds. This may come about as a failure of 
normal growth factor synthesis, and thus an increased breakdown of growth 
factors within a wound environment that is markedly proteolytic because of 
overexpression of protease activity or a failure of the normal antiprotease 
inhibitor mechanisms. 
 Fibroblasts from chronic wounds also have been found to have decreased 
proliferative potential, perhaps because of senescence or decreased expression 
of growth factor receptors.  
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Chronic wounds occur due to various etiologic factors, and several of the most 
common are discussed in the following sections. 
Malignant transformation of chronic ulcers can occur in any long-standing 
wound (Marjolin ulcer). Any wound that does not heal for a prolonged period 
of time is prone to malignant transformation.  
Malignant wounds are differentiated clinically from non-malignant wounds by 
the presence of overturned wound edges. In patients with suspected malignant 
transformations, biopsy of the wound edges must be performed to rule out 
malignancy. Cancers arising de novo in chronic wounds include both squamous 
and basal cell carcinomas 
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Pathology of Wound Healing 
Tissue Renewal, Regeneration and Repair  
Injury to cells and tissues sets in motion a series of events that contain the 
damage and initiate the healing process. 
 This process can be broadly separated into regeneration and repair . 
Regeneration results in the complete restitution of lost or damaged tissue; 
repair may restore some original structures but can cause structural 
derangements.  
In healthy tissues, healing, in the form of regeneration or repair, occurs after 
practically any insult that causes tissue destruction, and is essential for the 
survival of the organism. 
Tissues with high proliferative capacity, such as the hematopoietic system and 
the epithelia of the skin and gastrointestinal (GI) tract, renew themselves 
continuously and can regenerate after injury, as long as the stem cells of these 
tissues are not destroyed. 
Repair most often consists of a combination of regeneration and scar formation 
by the deposition of collagen.  
The relative contribution of regeneration and scarring in tissue repair depends 
on the ability of the tissue to regenerate and the extent of the injury. For 
instance, a superficial skin wound heals through the regeneration of the surface 
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epithelium. However, scar formation is the predominant healing process that 
occurs when the extracellular matrix (ECM) framework is damaged by severe 
injury . 
 Chronic inflammation that accompanies persistent injury also stimulates scar 
formation because of local production of growth factors and cytokines that 
promote fibroblast proliferation and collagen synthesis.  
The term fibrosis is used to describe the extensive deposition of collagen that 
occurs under these situations.  
ECM components are essential for wound healing, because they provide the 
framework for cell migration, maintain the correct cell polarity for the re-
assembly of multilayer structures, and participate in the formation of new blood 
vessels (angiogenesis). Cells in the ECM (fibroblasts, macrophages, and other 
cell types) produce growth factors, cytokines, and chemokines that are critical 
for regeneration and repair. 
 Although repair is a healing process, it may itself cause tissue dysfunction, as, 
for instance, in the development of atherosclerosis. 
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Cell Cycle and the Regulation of Cell Replication  
Cell proliferation is a tightly regulated process that involves a large number of 
molecules and interrelated pathways. 
 These are some salient features of the process of cellular proliferation. 
The replication of cells is stimulated by growth factors or by signaling from 
ECM components through integrins.  
To achieve DNA replication and division, the cell goes through a tightly 
controlled sequence of events known as the cell cycle.  
The cell cycle consists of G1 (presynthetic), S (DNA synthesis), G2 
(premitotic), and M (mitotic) phases.  
Quiescent cells which have not entered the cell cycle are in the G0 state. 
Each cell cycle phase is dependent on the proper activation and completion of 
the previous one, and the cycle stops at a place at which an essential gene 
function is deficient. Because of its central role in maintaining tissue 
homeostasis and regulating physiologic growth processes such as regeneration 
and repair, the cell cycle has multiple controls and redundancies, particularly 
during the transition between the G1 and S phases. These controls include 
activators and inhibitors, as well as sensors that are responsible for 
checkpoints. 
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Cells  enter G1 either from G0 (quiescent cells) or after completing mitosis 
(continuously replicating cells). 
 Quiescent cells first must go through the transition from G0 to G1, that 
functions as a gateway to the cell cycle. This transition involves the 
transcriptional activation of a large set of genes, including different proto-
oncogenes and genes required for ribosome synthesis and protein translation. 
Cells in G1 progress through the cycle and reach a critical stage at the G1/S 
transition, known as a restriction point, a ratelimiting step for replication . After 
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passing this restriction point, normal cells become irreversibly committed to 
DNA replication.  
Progression through the cell cycle, particularly at the G1/S transition, is tightly 
regulated by proteins called cyclins and associated enzymes called cyclin-
dependent kinases (CDKs). CDKs acquire catalytic activity by binding to and 
forming complexes with the cyclins. Activated CDKs in these complexes drive 
the cell cycle by phosphorylating proteins that are critical for cell cycle 
transitions.  
The activity of cyclin-CDK complexes is tightly regulated by CDK inhibitors. 
Some growth factors shut off production of these inhibitors. 
 Embedded in the cell cycle are surveillance mechanisms that are geared 
primarily at sensing damage to DNA and chromosomes. These quality control 
checks are called checkpoints; they ensure that cells with damaged DNA or 
chromosomes do not complete replication. 
 The G1/S checkpoint monitors the integrity of  DNA before replication, 
whereas the G2/M checkpoint checks DNA after replication and monitors 
whether the cell can safely enter mitosis. 
 When cells sense DNA damage, checkpoint activation delays the cell cycle 
and triggers DNA repair mechanisms. If  DNA damage is too severe to be 
repaired, the cells are eliminated by apoptosis, or enter a non-replicative state 
called senescence, primarily through p53-dependent mechanisms.  
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GROWTH FACTORS  
The proliferation of many cell types is driven by polypeptides known as growth 
factors. These factors, which can have restricted or multiple cell targets, may 
also promote cell survival, locomotion, contractility, differentiation, and 
angiogenesis, activities that may be as important as their growth-promoting 
effects.  
All growth factors function as ligands that bind to specific receptors, which 
deliver signals to the target cells. These signals stimulate the transcription of 
genes that may be silent in resting cells, including genes that control cell cycle 
entry and progression 
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Factors and Cytokines Involved in Regeneration and Wound Healing 
Growth Factor Symbol Source Functions 
Epidermal 
growth factor 
EGF Platelets, 
macrophages, 
saliva, urine, 
milk, plasma 
Mitogenic for keratinocytes 
and fibroblasts; stimulates 
keratinocyte migration and 
granulation tissue 
formation 
Transforming 
growth factor α 
TGF-α Macrophages, T 
lymphocytes, 
keratinocytes, and 
many tissues 
Similar to EGF; stimulates 
replication of hepatocytes 
and most epithelial cells 
Heparin-binding 
EGF 
HB-
EGF 
Macrophages, 
mesenchymal cells 
Keratinocyte replication 
Hepatocyte 
growth 
factor/scatter 
factor 
HGF Mesenchymal cells Enhances proliferation of 
hepatocytes, epithelial cells, 
and endothelial cells; 
increases cell motility, 
keratinocyte replication 
Vascular 
endothelial cell 
growth factor 
VEGF Many types of cells Increases vascular 
permeability; mitogenic for 
endothelial cells (see Table 
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Growth Factor Symbol Source Functions 
(isoforms A, B, C, 
D) 
3-3 ); angiogenesis 
Platelet-derived 
growth factor 
(isoforms A, B, C, 
D) 
PDGF Platelets, 
macrophages, 
endothelial cells, 
keratinocytes, 
smooth muscle 
cells 
Chemotactic for PMNs, 
macrophages, fibroblasts, 
and smooth muscle cells; 
activates PMNs, 
macrophages, and 
fibroblasts; mitogenic for 
fibroblasts, endothelial cells, 
and smooth muscle cells; 
stimulates production of 
MMPs, fibronectin, and HA; 
stimulates angiogenesis and 
wound contraction 
Fibroblast growth 
factor 1 (acidic), 2 
(basic), and 
family 
FGF Macrophages, mast 
cells, T 
lymphocytes, 
endothelial cells, 
fibroblasts 
Chemotactic for fibroblasts; 
mitogenic for fibroblasts and 
keratinocytes; stimulates 
keratinocyte migration, 
angiogenesis, wound 
contraction, and matrix 
deposition 
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Growth Factor Symbol Source Functions 
Transforming 
growth factor β 
(isoforms 1, 2, 3); 
other members of 
the family are 
BMPs and activin 
TGF-β Platelets, T 
lymphocytes, 
macrophages, 
endothelial cells, 
keratinocytes, 
smooth muscle 
cells, fibroblasts 
Chemotactic for PMNs, 
macrophages, lymphocytes, 
fibroblasts, and smooth 
muscle cells; stimulates 
TIMP synthesis, 
angiogenesis, and fibroplasia; 
inhibits production of MMPs 
and keratinocyte proliferation 
Keratinocyte 
growth factor 
(also called FGF-
7) 
KGF Fibroblasts Stimulates keratinocyte 
migration, proliferation, and 
differentiation 
Tumor necrosis 
factor 
TNF Macrophages, mast 
cells, T 
lymphocytes 
Activates macrophages; 
regulates other cytokines; 
multiple functions 
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Epidermal Growth Factor (EGF) 
EGF has receptor called epidermal growth factor receptor (EGFR). 
EGF is mitogenic for a variety of epithelial cells, hepatocytes, and fibroblasts, 
and is widely distributed in tissue secretions and fluids. 
In healing wounds of the skin, EGF is produced by keratinocytes, 
macrophages, and other inflammatory cells that migrate into the area. 
The “EGF receptor” is actually a family of four membrane receptors with 
intrinsic tyrosine kinase activity. The best-characterized EGFR is referred to as 
EGFR1, ERB B1, or simply EGFR. It responds to EGF, TGF-α, and other 
ligands of the EGF family, such as HB-EGF (heparin-binding EGF) and 
amphiregulin.  
EGFR1 mutations and amplification have been detected in cancers of the lung, 
head and neck, and breast, glioblastomas, and other cancers, leading to the 
development of new types of treatments for these conditions.  
The ERB B2 receptor (also known as HER-2 or HER2/Neu), whose main 
ligand has not been identified, has received great attention because it is 
overexpressed in a subset of breast cancers and is an important therapeutic 
target 
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             Human epidermal growth factor gel 
 
 
 
 
 
Healing by Repair, Scar Formation and Fibrosis  
27 
 
If tissue injury is severe or chronic, and results in damage of both parenchymal 
cells and the stromal framework of the tissue, healing can not be accomplished 
by regeneration. Under these conditions, the main healing process is repair by 
deposition of collagen and other ECM components, causing the formation of a 
scar.  
In contrast to regeneration which involves the restitution of tissue components, 
repair is a fibroproliferative response that “patches” rather than restores the 
tissue.  
The term scar is most often used in connection to wound healing in the skin, 
but is also used to describe the replacement of parenchymal cells in any tissue 
by collagen, as in the heart after myocardial infarction. Repair by connective 
tissue deposition includes the following basic features:  
   •    Inflammation 
   •    angiogenesis, 
   •    migration and proliferation of fibroblasts, 
   •    scar formation 
   •    connective tissue remodeling. 
The inflammatory reaction elicited by the injury contains the damage, removes 
injured tissue, and promotes the deposition of ECM components in the area of 
injury, at the same time that angiogenesis is stimulated. However, if the 
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damage persists, inflammation becomes chronic, leading to an excess 
deposition of connective tissue known as fibrosis. In most healing processes, a 
combination of repair and regeneration occurs. The relative contributions of 
repair and regeneration are influenced by:  
(1) the proliferative capacity of the cells of the tissue;  
(2) the integrity of the extracellular matrix; and  
(3) the resolution or chronicity of the injury and inflammation. 
CUTANEOUS WOUND HEALING  
Cutaneous wound healing is divided into three phases:  
1. inflammation, 
2. proliferation, and  
3. maturation.  
 
These phases overlap, and their separation is somewhat arbitrary, but they help 
to understand the sequence of events that take place in the healing of skin 
wounds. 
 The initial injury causes platelet adhesion and aggregation and the formation 
of a clot in the surface of the wound, leading to inflammation.  
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In the proliferative phase there is formation of granulation tissue, proliferation 
and migration of connective tissue cells, and re-epithelialization of the wound 
surface. Maturation involves ECM deposition, tissue remodeling, and wound 
contraction.  
The simplest type of cutaneous wound repair is the healing of a clean, 
uninfected surgical incision approximated by surgical sutures. Such healing is 
referred to as healing by primary union or by first intention..  
Re-epithelialization to close the wound occurs with formation of a relatively 
thin scar. The repair process is more complicated in excisional wounds that 
create large defects on the skin surface, causing extensive loss of cells and 
tissue. The healing of these wounds involves a more intense inflammatory 
reaction, the formation of abundant granulation tissue, and extensive collagen 
deposition, leading to the formation of a substantial scar, which generally 
contracts. This form of healing is referred to as healing by secondary union or 
by second intention.  
Despite these differences, the basic mechanisms of healing by primary (first 
intention) and secondary (second intention) union are similar.   
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Wound healing by first intension and second intension  
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Growth Factors and Cytokines Affecting Various Steps in Wound Healing 
Monocyte chemotaxis Chemokines, TNF, PDGF, FGF, TGF-β 
Fibroblast migration/replication PDGF, EGF, FGF, TGF-β, TNF, IL-1 
Keratinocyte replication HB-EGF, FGF-7, HGF 
Angiogenesis VEGF, angiopoietins, FGF 
Collagen synthesis TGF-β, PDGF 
Collagenase secretion PDGF, FGF, TNF; TGF-β inhibits 
HB-EGF, heparin-binding EGF; IL-1, interleukin 1; TNF, tumor necrosis 
factor;. 
 
Formation of Granulation Tissue.  
Fibroblasts and vascular endothelial cells proliferate in the first 24 to 72 hours 
of the repair process to form a specialized type of tissue called granulation 
tissue, which is a hallmark of tissue repair.  
Its characteristic histologic feature is the presence of new small blood vessels 
(angiogenesis) and the proliferation of fibroblasts.  
These new vessels are leaky, allowing the passage of plasma proteins and fluid 
into the extravascular space. Thus, new granulation tissue is often edematous. 
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 Granulation tissue progressively invades the incision space; the amount of 
granulation tissue that is formed depends on the size of the tissue deficit 
created by the wound and the intensity of inflammation.  
Hence, it is much more prominent in healing by secondary union. By 5 to 7 
days, granulation tissue fills the wound area and neovascularization is maximal.  
 
 
Cell Proliferation and Collagen Deposition.  
Neutrophils are largely replaced by macrophages by 48 to 96 hours.  
Macrophages are key cellular constituents of tissue repair, clearing 
extracellular debris, fibrin, and other foreign material at the site of repair, 
and promoting angiogenesis and ECM deposition.  
 
Full epithelialization of the wound surface is much slower in healing by 
secondary union because the gap to be bridged is much greater. Subsequent 
epithelial cell proliferation thickens the epidermal layer. .. 
Scar Formation.  
The leukocytic infiltrate, edema, and increased vascularity largely disappear 
during the second week.  
Blanching begins, accomplished by the increased accumulation of collagen 
within the wound area and regression of vascular channels. 
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Mainly, the original granulation tissue scaffolding is converted into a pale, 
avascular scar, composed of spindle-shaped fibroblasts, dense collagen, 
fragments of elastic tissue, and other ECM components.  
The dermal appendages that have been destroyed in the line of the incision are 
permanently lost, although in rats new hair follicles may develop in large 
healing wounds under Wnt stimulation. This result suggests that, with 
appropriate treatment procedures, regrowth of skin appendages during wound 
healing might be achieved in humans.  
By the end of the first month, the scar is made up of acellular connective tissue 
devoid of inflammatory infiltrate, covered by intact epidermis. 
 
Wound Contraction.  
Wound contraction generally occurs in large surface wounds.  
The contraction helps to close the wound by decreasing the gap between its 
dermal edges and by reducing the wound surface area. Hence, it is an important 
feature in healing by secondary union.  
. 
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Connective Tissue Remodeling.  
The replacement of granulation tissue with a scar involves changes in the 
composition of the ECM. The balance between ECM synthesis and degradation 
results in remodeling of the connective tissue framework – an important feature 
of tissue repair. Some of the growth factors that stimulate synthesis of collagen 
and other connective tissue molecules also modulate the synthesis and 
activation of metalloproteinases, enzymes that degrade these ECM 
components. 
.Recovery of Tensile Strength.  
Fibrillar collagens (mostly type I collagen) form a major portion of the 
connective tissue in repair sites and are essential for the development of 
strength in healing wounds. 
 Net collagen accumulation, however, depends not only on increased collagen 
synthesis but also on decreased degradation.  
When sutures are removed from an incisional surgical wound, usually at the 
end of the first week, wound strength is approximately 10% that of unwounded 
skin. 
 Wound strength increases rapidly over the next 4 weeks, slows down at 
approximately the third month after the original incision, and reaches a plateau 
at about 70% to 80% of the tensile strength of unwounded skin. 
35 
 
 Lower tensile strength in the healed wound area may persist for life. The 
recovery of tensile strength results from the excess of collagen synthesis over 
collagen degradation during the first 2 months of healing, and, at later times, 
from structural modifications of collagen fibers (cross-linking, increased fiber 
size) after collagen synthesis ceases. 
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LOCAL AND SYSTEMIC FACTORS THAT INFLUENCE WOUND 
HEALING  
Factors Affecting Wound Healing 
Systemic factors  
Age 
Nutrition  
Trauma  
Metabolic diseases 
 Immunosuppression 
Connective tissue disorders 
Smoking 
Local factors 
  Mechanical injury 
  Infection 
   Edema  
  Ischemia/necrotic tissue 
  Topical agents 
  Ionizing radiation 
  Low oxygen tension 
  Foreign bodies 
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Factors Affecting Wound Healing 
Advanced Age 
Aging produces intrinsic physiologic changes that result in delayed or impaired 
wound healing. The increased incidence of cardiovascular disease, metabolic 
diseases (diabetes mellitus, malnutrition, and vitamin deficiencies), cancer, and 
the widespread use of drugs that impair wound healing may all contribute to 
the higher incidence of wound problems in the elderly.  
Hypoxia, Anemia, and Hypoperfusion 
Low oxygen tension has a profoundly deleterious effect on all aspects of 
wound healing. Fibroplasia, although stimulated initially by the hypoxic wound 
environment, is significantly impaired by local hypoxia. Optimal collagen 
synthesis requires oxygen as a cofactor, particularly for the hydroxylation 
steps. Increasing subcutaneous oxygen tension levels by increasing the fraction 
of inspired oxygen (FiO2) of inspired air for brief periods during and 
immediately after surgery results in enhanced collagen deposition and in 
decreased rates of wound infection after elective surgery. 
Major factors affecting local oxygen delivery include hypoperfusion either for 
systemic reasons (low volume or cardiac failure) or due to local causes (arterial 
insufficiency, local vasoconstriction, or excessive tension on tissues).  
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The level of vasoconstriction of the subcutaneous capillary bed is exquisitely 
responsive to fluid status, temperature, and hyperactive sympathetic tone as is 
often induced by postoperative pain. Correction of these factors can have a 
remarkable influence on wound outcome, particularly on decreasing wound 
infection rates. Mild to moderate normovolemic anemia does not appear to 
adversely affect wound oxygen tension and collagen synthesis, unless the 
hematocrit falls below 15%. 
Steroids and Chemotherapeutic Drugs 
Large doses or chronic usage of glucocorticoids reduce collagen synthesis and 
wound strength.The major effect of steroids is to inhibit the inflammatory 
phase of wound healing (angiogenesis, neutrophil and macrophage migration, 
and fibroblast proliferation) and the release of lysosomal enzymes.It inhibit 
epithelialization and contraction and contribute to increased rates of wound 
infection, regardless of the time of administration. Steroid-delayed healing of 
cutaneous wounds can be stimulated to epithelialize by topical application of 
vitamin A. Collagen synthesis of steroid-treated wounds also can be stimulated 
by vitamin A.  
Metabolic Disorders 
Diabetes mellitus is the best known of the metabolic disorders contributing to 
increased rates of wound infection and failure.  
Uremia also has been associated with disordered wound healing.  
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Nutrition 
Poor nutritional intake or lack of individual nutrients significantly alters many 
aspects of wound healing.  
The clinician must pay close attention to the nutritional status of patients with 
wounds, as wound failure or wound infections may be no more than a 
reflection of poor nutrition.. 
Clinically, it is extremely rare to encounter pure energy or protein malnutrition, 
and the vast majority of patients exhibit combined protein-energy malnutrition. 
Such patients have diminished hydroxyproline accumulation (an index of 
collagen deposition) into subcutaneously implanted polytetrafluoroethylene 
tubes when compared to normally nourished patients.  
The possible role of single amino acids in enhanced wound healing has been 
studied for the last several decades. Arginine appears most active in terms of 
enhancing wound fibroplasia. Arginine deficiency results in decreased wound-
breaking strength and wound collagen accumulation. The main effect of 
arginine on wound healing is to enhance wound collagen deposition.  
As increases in breaking strength during the first weeks of healing are directly 
related to new collagen synthesis, arginine supplementation may result in an 
improvement in wound strength as a consequence of enhanced collagen 
deposition. 
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The vitamins most closely involved with wound healing are vitamin C and 
vitamin A. Scurvy, or vitamin C deficiency, leads to a defect in wound 
healing, particularly via a failure in collagen synthesis and cross-linking. 
Biochemically, vitamin C is required for the conversion of proline and lysine to 
hydroxyproline and hydroxylysine, respectively.  
Vitamin C deficiency has also been associated with an increased incidence of 
wound infection, and if wound infection does occur, it tends to be more severe. 
These effects are believed to be due to an associated impairment in neutrophil 
function, decreased complement activity, and decreased walling-off of bacteria 
secondary to insufficient collagen deposition.  
Vitamin A deficiency impairs wound healing, whereas supplemental vitamin A 
benefits wound healing in nondeficient humans and animals.  
Vitamin A increases the inflammatory response in wound healing, probably by 
increasing the lability of lysosomal membranes. There is an increased influx of 
macrophages, with an increase in their activation and increased collagen 
synthesis. Vitamin A directly increases collagen production and epidermal 
growth factor receptors when it is added in vitro to cultured fibroblasts. 
Vitamin A also can restore wound healing that has been impaired by diabetes, 
tumor formation, cyclophosphamide, and radiation 
The connections between specific minerals and trace elements and deficits in 
wound healing are complex. Frequently, deficiencies are multiple and include 
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macronutrient deficiencies. The specific trace element may function as a 
cofactor or part of an enzyme that is essential for homeostasis and wound 
healing.  
Zinc is the most well-known element in wound healing and has been used 
empirically in dermatologic conditions for centuries. It is essential for wound 
healing in animals and humans. There are more than 150 known enzymes for 
which zinc is either an integral part or an essential cofactor, and many of these 
enzymes are critical to wound healing. With zinc deficiency there is decreased 
fibroblast proliferation, decreased collagen synthesis, impaired overall wound 
strength, and delayed epithelialization. These defects are reversed by zinc 
supplementation. To date, no study has shown improved wound healing with 
zinc supplementation in patients who are not zinc deficient. 
Infections 
Wound infections continue to represent a major medical problem, both in terms 
of how they affect the outcome of surgical procedures (surgical site infections), 
and for their impact on the length of hospital stay and medical costs. 
Many otherwise successful surgical operations fail because of the development 
of wound infections. Cosmetically, infections can lead to disfiguring, unsightly, 
or delayed closures. 
Antibiotic prophylaxis is most effective when adequate concentrations of 
antibiotic are present in the tissues at the time of incision, and assurance of 
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adequate preoperative antibiotic dosing and timing has become a significant 
hospital performance measure. Addition of antibiotics after operative 
contamination has occurred is clearly ineffective in preventing postoperative 
wound infections. 
PATHOLOGIC ASPECTS OF REPAIR  
Complications in wound healing can arise from abnormalities in any of the 
basic components of the repair process. These aberrations can be grouped into 
three general categories:  
(1) deficient scar formation,  
(2) excessive formation of the repair components, and 
 (3) formation of contractures.  
   
•    Inadequate formation of granulation tissue or assembly of a scar can lead 
to two types of complications: wound dehiscence and ulceration.. 
   
•    Excessive formation of the components of the repair process can give 
rise to hypertrophic scars and keloids. The accumulation of excessive 
amounts of collagen may give rise to a raised scar known as a 
hypertrophic scar; if the scar tissue grows beyond the boundaries of the 
original wound and does not regress, it is called a keloid. Keloid 
formation seems to be an individual predisposition, and for unknown 
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reasons this aberration is somewhat more common in African 
Americans. Hyperthrophic scars generally develop after thermal or 
traumatic injury that involves the deep layers of the dermis.  
   
•    Contraction in the size of a wound is an important part of the normal 
healing process. An exaggeration of this process gives rise to contracture 
and results in deformities of the wound and the surrounding tissues. 
Contractures are particularly prone to develop on the palms, the soles, 
and the anterior aspect of the thorax. Contractures are commonly seen 
after serious burns and can compromise the movement of joints. 
 
 
Fibrosis  
Deposition of collagen is part of normal wound healing. However, the term 
fibrosis is used more broadly to denote the excessive deposition of collagen and 
other ECM components in a tissue.  
The terms scar and fibrosis are used interchangeably, but fibrosis most often 
indicates the deposition of collagen in chronic diseases. The basic mechanisms 
that occur in the development of fibrosis associated with chronic inflammatory 
diseases are generally similar to the mechanisms of skin wound healing..  
.  
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DIABETES MELLITUS (DM) 
Diabetes mellitus  refers to a group of common metabolic disorders that 
share the phenotype of hyperglycemia. Several distinct types of DM exist and 
are caused by a complex interaction of genetics and environmental factors. 
Depending on the etiology of the DM, factors contributing to hyperglycemia 
include reduced insulin secretion, decreased glucose utilization, and increased 
glucose production. The metabolic dysregulation associated with DM causes 
secondary pathophysiologic changes in multiple organ systems that impose a 
tremendous burden on the individual with diabetes and on the health care 
system.  
DIAGNOSIS 
Blood glucose values are normally maintained in a very narrow range, usually 
70 to 120 mg/dL. The diagnosis of diabetes is established by noting elevation 
of blood glucose by any one of three criteria: 
 
1. A random glucose concentration greater than 200 mg/dL, with classical 
signs and symptoms 
 
2. A fasting glucose concentration greater than 126 mg/dL on more than one 
occasion 
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3. An abnormal oral glucose tolerance test (OGTT), in which the glucose 
concentration is greater than 200 mg/dL 2 hours after a standard 
carbohydrate load 
.PATHOGENESIS OF TYPE 2 DIABETES MELLITUS  
Type 2 diabetes is a prototypic multifactorial complex disease.  
Environmental factors, such as a sedentary life style and dietary habits, 
unequivocally play a role, as will become evident when the association with 
obesity is considered.  
The two metabolic defects that characterize type 2 diabetes are  
1. a decreased response of peripheral tissues to insulin (insulin 
resistance) and  
2. β-cell dysfunction that is manifested as inadequate insulin secretion 
in the face of insulin resistance and hyperglycemia.  
Gangrene of the lower extremities, as a result of advanced vascular disease, 
is about 100 times more common in diabetics than in the general population.  
The larger renal arteries are also subject to severe atherosclerosis, but the most 
damaging effect of diabetes on the kidneys is exerted at the level of the 
glomeruli and the microcirculation 
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Diabetic Microangiopathy: 
 One of the most consistent morphologic features of diabetes is diffuse 
thickening of basement membranes. The thickening is most evident in the 
capillaries of the skin, skeletal muscle, retina, renal glomeruli, and renal 
medulla. However, it may also be seen in such nonvascular structures as renal 
tubules, the Bowman capsule, peripheral nerves, and placenta. It should be 
noted that despite the increase in the thickness of basement membranes, 
diabetic capillaries are more leaky than normal to plasma proteins. The 
microangiopathy underlies the development of diabetic nephropathy, 
retinopathy, and some forms of neuropathy. An indistinguishable 
microangiopathy can be found in aged nondiabetic patients but rarely to the 
extent seen in patients with long-standing diabetes. 
Diabetic Wounds 
Diabetes mellitus impairs wound healing at all stages of the process. 10 to 15% 
of diabetic patients run the risk of developing ulcers. The major contributors to 
the formation of diabetic ulcers include neuropathy, foot deformity, and 
ischemia.  
It is estimated that 60 to 70% of diabetic ulcers are due to neuropathy, 15 to 
20% are due to ischemia, and another 15 to 20% are due to a combination of 
both. The neuropathy is both sensory and motor, and is secondary to 
persistently elevated glucose levels. The loss of sensory function allows 
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unrecognized injury to occur from ill-fitting shoes, foreign bodies, or other 
trauma.  
The motor neuropathy or Charcot foot leads to collapse or dislocation of the 
interphalangeal or metatarsophalangeal joints, causing pressure on areas with 
little protection. There is also severe micro- and macrovascular circulatory 
impairment. 
Tissue hypoxia, as indicated by reduced dorsal foot transcutaneous oxygen 
tension, is a consequence of vascular disease and has been well demonstrated 
in diabetic patients. 
Diabetic patients are prone to repeated trauma as a result of the diabetic 
neuropathy that affects both sensory and motor function in both the somatic 
and autonomic pathways.  
Furthermore, diabetics are susceptible to infection because of an attenuated 
inflammatory response, impaired chemotaxis, and inefficient bacterial killing. 
Infection also increases local tissue metabolism, thus further imposing a burden 
on an already tenuous blood supply and thereby amplifying the risk for tissue 
necrosis.  
Lymphocyte and leukocyte function is impaired, and there is increased 
collagen degradation and decreased collagen deposition. The collagen that is 
formed is more brittle than normal collagen, probably because of glycosylation 
from the increased levels of glucose present in the ECM 
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Once ulceration occurs, the chances of healing are poor. The treatment of 
diabetic wounds involves local and systemic measures. Achievement of 
adequate blood sugar levels is very important. Most diabetic wounds are 
infected, and eradication of the infectious source is paramount to the success of 
healing. Treatment should address the possible presence of osteomyelitis, and 
should employ antibiotics that achieve adequate levels both in soft tissue and 
bone. Wide débridement of all necrotic or infected tissue is another cornerstone 
of treatment. Topical application of Human epidermal growth factor has met 
with significant success in achieving closure or allograft.  
The application of engineered skin allograft substitutes, although expensive, 
has also shown some significant success. Prevention and, specifically, foot care 
play an important role in the management of diabetics. 
Treatment of  Diabetic Wounds 
Local Care 
Management of acute wounds begins with obtaining a careful history of the 
events surrounding the injury. The history is followed by a meticulous 
examination of the wound. Examination should assess the depth and 
configuration of the wound, the extent of nonviable tissue, and the presence of 
foreign bodies and other contaminants. Examination of the wound may require 
irrigation and débridement of the edges of the wound, and is facilitated by use 
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of local anesthesia. Antibiotic administration and tetanus prophylaxis may be 
needed, and planning the type and timing of wound repair should take place. 
After completion of the history, examination, and administration of tetanus 
prophylaxis, the wound should be meticulously anesthetized.. 
 Irrigation to visualize all areas of the wound and remove foreign material is 
best accomplished with normal saline. High-pressure wound irrigation is more 
effective in achieving complete débridement of foreign material and nonviable 
tissues.  
Having ensured hemostasis and adequate débridement of nonviable tissues and 
removal of any remaining foreign bodies, irregular, macerated, or beveled 
wound edges should be débrided in order to provide a fresh edge for 
reapproximation..  
After wound healing in areas of significant tissue loss, rotation of adjacent 
musculocutaneous flaps may be required to provide sufficient tissue mass for 
closure. These musculocutaneous flaps may be based on intrinsic blood supply, 
or may be moved from distant sites as free flaps and anastomosed into the local 
vascular bed. In areas with significant superficial tissue loss, split-thickness 
skin grafting (placed in a delayed manner to assure an adequate tissue bed) may 
be required and will speed formation of an intact epithelial barrier to fluid loss 
and infection.  
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Split-thickness skin grafts are readily obtained using manual or mechanical 
dermatomes, and the grafts may be "meshed" in order to increase the surface 
area of their coverage. It is essential to ensure hemostasis of the underlying 
tissue bed before placement of split-thickness skin grafts, as the presence of a 
hematoma below the graft will prevent the graft from taking, resulting in 
sloughing of the graft.  
Antibiotics 
Antibiotics should be used only when there is an obvious wound infection. 
Most wounds are contaminated or colonized with bacteria. The presence of a 
host response constitutes an infection and justifies the use of antibiotics. Signs 
of infection to look for include erythema, cellulitis, swelling, and purulent 
discharge. Indiscriminate use of antibiotics should be avoided to prevent 
emergence of multidrug-resistant bacteria. Antibiotic treatment of wounds must 
be based on organisms suspected to be found within the infected wound and the 
patient's overall immune status. Patient should be treated with antibiotics 
according to culture and sensitivity from wound. 
Dressings 
The main purpose of wound dressings is to provide the ideal environment for 
wound healing. The dressing should facilitate the major changes taking place 
during healing to produce an optimally healed wound. Although the ideal 
dressing is still not a clinical reality, technological advances are promising . 
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 Desired Characteristics of Wound Dressings 
 
Promote wound healing (maintain moist environment) 
Conformability 
Pain control 
Odour control 
Nonallergenic and nonirritating 
Permeability to gas 
Safety 
Non traumatic removal 
Cost-effectiveness 
Convenience 
 
 
Covering a wound with a dressing mimics the barrier role of epithelium and 
prevents further damage. In addition, application of compression provides 
hemostasis and limits edema.  
Occlusion of a wound with dressing material helps healing by controlling the 
level of hydration and oxygen tension within the wound. It also allows transfer 
of gases and water vapor from the wound surface to the atmosphere.  
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Occlusion affects both the dermis and epidermis, and it has been shown that 
exposed wounds are more inflamed and develop more necrosis than covered 
wounds. Occlusion also helps in dermal collagen synthesis and epithelial cell 
migration and limits tissue desiccation. As it may enhance bacterial growth, 
occlusion is contraindicated in infected and highly exudative wounds.  
Dressings can be classified as primary or secondary.  
A primary dressing is placed directly on the wound and may provide 
absorption of fluids and prevent desiccation, infection, and adhesion of a 
secondary dressing.  
A secondary dressing is one that is placed on the primary dressing for further 
protection, absorption, compression, and occlusion.  
Many types of dressings exist and are designed to achieve certain clinically 
desired endpoints. 
Absorbent Dressings 
Accumulation of wound fluid can lead to maceration and bacterial overgrowth. 
Ideally, the dressing should absorb without getting soaked through, as this 
would permit bacteria from the outside to enter the wound.  
The dressing must be designed to match the exudative properties of the wound 
and may include cotton, wool, and sponge. 
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Nonadherent Dressings 
Nonadherent dressings are impregnated with paraffin, petroleum jelly, or 
water-soluble jelly for use as nonadherent coverage. A secondary dressing must 
be placed on top to seal the edges and prevent desiccation and infection. 
Occlusive and Semiocclusive Dressings 
Occlusive and semiocclusive dressings provide a good environment for clean, 
minimally exudative wounds. These film dressings are waterproof and 
impervious to microbes, but permeable to water vapor and oxygen. 
Hydrophilic and Hydrophobic Dressings 
Hydrophilic and hydrophobic dressings are components of a composite 
dressing. Hydrophilic dressing aids in absorption, whereas a hydrophobic 
dressing is waterproof and prevents absorption. 
Hydrocolloid and Hydrogel Dressings 
Hydrocolloid and hydrogel dressings attempt to combine the benefits of 
occlusion and absorbency.  
Hydrocolloids and hydrogels form complex structures with water, and fluid 
absorption occurs with particle swelling, which aids in atraumatic removal of 
the dressing.  
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Absorption of exudates by the hydrocolloid dressing leaves a yellowish-brown 
gelatinous mass after dressing removal that can be washed off. Hydrogel is a 
cross-linked polymer that has high water content. Hydrogels allow a high rate 
of evaporation without compromising wound hydration, which makes them 
useful in burn treatment. 
Alginates 
Alginates are derived from brown algae and contain long chains of 
polysaccharides containing mannuronic and glucuronic acid. The ratios of these 
sugars vary with the species of algae used, as well as the season of harvest. 
Processed as the calcium form, alginates turn into soluble sodium alginate 
through ion exchange in the presence of wound exudates. The polymers gel, 
swell, and absorb a great deal of fluid. Alginates are being used when there is 
skin loss, in open surgical wounds with medium exudation, and on full-
thickness chronic wounds. 
Absorbable Materials 
Absorbable materials are mainly used within wounds as hemostats and include 
collagen, gelatin, oxidized cellulose, and oxidized regenerated cellulose. 
Medicated Dressings 
Medicated dressings have long been used as a drug-delivery system. Agents 
delivered in the dressings include benzoyl peroxide, zinc oxide, neomycin, and 
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bacitracin-zinc. These agents have been shown to increase epithelialization by 
28%. 
The type of dressing to be used depends on the amount of wound drainage.  
A nondraining wound can be covered with a semiocclusive dressing. Drainage 
of less than 1 to 2 mL/d may require a semiocclusive or absorbent nonadherent 
dressing. Moderately draining wounds (3 to 5 mL/d) can be dressed with a 
nonadherent primary layer plus an absorbent secondary layer plus an occlusive 
dressing to protect normal tissue. Heavily draining wounds (>5 mL/d) require a 
similar dressing to moderately draining wounds, but with the addition of a 
highly absorbent secondary layer. 
Mechanical Devices 
Mechanical therapy augments and improves on certain functions of dressings, 
in particular the absorption of exudates and control of odor. The vacuum-
assisted closure system assists in wound closure by applying localized negative 
pressure to the surface and margins of the wound. The negative pressure 
therapy is applied to a special foam dressing cut to the dimensions of the 
wound and positioned in the wound cavity or over a flap or graft. The 
continuous negative pressure is very effective in removing exudates from the 
wound. This form of therapy has been found to be effective for chronic open 
wounds (diabetic ulcers and stages 3 and 4 pressure ulcers), acute and 
traumatic wounds, flaps and grafts, and subacute wounds (i.e., dehisced 
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incisions), although more randomized trials need to be carried out to confirm 
efficacy. 
Skin Replacements 
All wounds require coverage in order to prevent evaporative losses and 
infection and to provide an environment that promotes healing. Both acute and 
chronic wounds may demand use of skin replacement, and several options are 
available. 
Skin Grafts 
Skin grafts have long been used to treat both acute and chronic wounds. Split- 
or partial-thickness grafts consist of the epidermis plus part of the dermis, 
whereas full-thickness grafts retain the entire epidermis and dermis. 
Autologous grafts (autografts) are transplants from one site on the body to 
another.  
Allogeneic grafts (allografts, homografts) are transplants from a living 
nonidentical donor or cadaver to the host; and  
xenogeneic grafts (heterografts) are taken from another species (e.g., porcine). 
 Split-thickness grafts require less blood supply to restore skin function. The 
dermal component of full-thickness grafts lends mechanical strength and resists 
wound contraction better, resulting in improved cosmesis.  
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Allogeneic and xenogeneic grafts require the availability of tissue, are subject 
to rejection, and may contain pathogens. 
The use of skin grafts or bioengineered skin substitutes and other innovative 
treatments (e.g., topically applied growth factors, systemic agents, and gene 
therapy) cannot be effective unless the wound bed is adequately prepared. This 
may include débridement to remove necrotic or fibrinous tissue, control of 
edema, revascularization of the wound bed, decreasing the bacterial burden, 
and minimizing or eliminating exudate. Temporary placement of allografts or 
xenografts may be used to prepare the wound bed.  
Skin Substitutes 
Originally devised to provide coverage of extensive wounds with limited 
availability of autografts, skin substitutes also have gained acceptance as 
natural dressings. Manufactured by tissue engineering, they combine novel 
materials with living cells to provide functional skin substitutes, providing a 
bridge between dressings and skin grafts. 
Skin substitutes have theoretical advantages of being readily available, not 
requiring painful harvest, and they may be applied freely or with surgical 
suturing. In addition, they promote healing, either by stimulating host cytokine 
generation or by providing cells that may also produce growth factors locally.  
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Their disadvantages include limited survival, high cost, and the need for 
multiple applications Allografting, albeit with a very thin graft, may at times be 
required to accomplish complete coverage. 
 
Desired Features of Tissue-Engineered Skin 
 
Rapid re-establishment of functional skin (epidermis/dermis) 
Receptive to body's own cells (e.g., rapid "take" and integration) 
Graftable by a single, simple procedure 
Graftable on chronic or acute wounds 
Engraftment without use of extraordinary clinical intervention (i.e., 
immunosuppression) 
 
 
A variety of skin substitutes are available, each with its own set of advantages 
and disadvantages; however, the ideal skin substitute has yet to be developed. 
The development of newer composite substitutes, which provide both the 
dermal and epidermal components essential for permanent skin replacement, 
may represent an advance toward that goal.  
The acellular (e.g., native collagen or synthetic material) component acts as a 
scaffold, promotes cell migration and growth, and activates tissue regeneration 
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and remodeling. The cellular elements re-establish lost tissue and associated 
function, synthesize extracellular matrix components, produce essential 
mediators such as cytokines and growth factors, and promote proliferation and 
migration. 
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Advantages and Disadvantages of Various Bioengineered Skin Substitutes 
 
Skin Substitute Advantages Disadvantages 
Cultured allogeneic 
keratinocyte graft  
No biopsy needed Unstable 
"Off the shelf" 
availability 
Does not prevent wound 
contracture 
Provides wound 
coverage 
Inadequate cosmesis 
Promotes healing Possibility of disease 
transmission 
  Fragile 
Bioengineered dermal 
replacement  
Prevents contracture Limited ability to drive re-
epithelialization 
Good prep for graft 
application 
Largely serves as 
temporary dressing 
Cultured bilayer skin 
equivalent  
More closely mimics 
normal anatomy 
Cost 
Does not need 
secondary procedure 
Short shelf life 
Easily handled True engraftment 
questionable 
Can be sutured, 
meshed, etc. 
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Cultured epithelial autografts (CEAs) represent expanded autologous or 
homologous keratinocytes. CEAs are expanded from a biopsy of the patient's 
own skin, will not be rejected, and can stimulate re-epithelialization as well as 
the growth of underlying connective tissue.  
Keratinocytes harvested from a biopsy roughly the size of a postage stamp are 
cultured with fibroblasts and growth factors and grown into sheets that can 
cover large areas and give the appearance of normal skin. Until the epithelial 
sheets are sufficiently expanded, the wound must be covered with an occlusive 
dressing or a temporary allograft or xenograft.  
The dermis regenerates very slowly, if at all, for full-thickness wounds, 
because the sheets are very fragile, difficult to work with, are susceptible to 
infection, and do not resist contracture well, leading to poor cosmetic results.  
CEAs are available from cadavers, unrelated adult donors, or from neonatal 
foreskins. Fresh or cryopreserved cultured allogeneic keratinocytes can be left 
in place long enough to be superseded by multiplying endogenous skin cells 
because, unlike allografts containing epidermal Langerhans cells, they do not 
express major histocompatibility antigens. Cryopreserved CEAs are readily 
available "off the shelf," and provide growth factors that may aid healing. 
However, like autologous keratinocyte sheets, the grafts lack the strength 
provided by a dermal component and pose a risk of disease transmission. 
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Viable fibroblasts can be grown on bioabsorbable or nonbioabsorbable meshes 
to yield living dermal tissue that can act as a scaffold for epidermal growth. 
Fibroblasts stimulated by growth factors can produce type I collagen and 
glycosaminoglycans (e.g., chondroitin sulfates), which adhere to the wound 
surface to permit epithelial cell migration, as well as adhesive ligands (e.g., the 
matrix protein fibronectin), which promote cell adhesion. This approach has the 
virtue of being less time-consuming and expensive than culturing keratinocyte 
sheets. There are a number of commercially available, bioengineered dermal 
replacements approved for use in burn treatment as well as other indications. 
Bioengineered skin substitutes have evolved from keratinocyte monolayers to 
dermal equivalents to split-thickness products with a pseudoepidermis and, 
most recently, to products containing both epidermal and dermal components 
that resemble the three-dimensional structure and function of normal skin 
Indicated for use with standard compression therapy in the treatment of venous 
insufficiency ulcers and for the treatment of neuropathic diabetic foot ulcers, 
these bilayered skin equivalents also are being used in a variety of wound care 
settings. 
Growth Factor Therapy 
It is believed that nonhealing wounds result from insufficient or inadequate 
growth factors in the wound environment. A simplistic solution would be to 
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flood the wound with single or multiple growth factors in order to "jump-start" 
healing and re-epithelialization.  
Although there is a large body of work demonstrating the effects of growth 
factors in animals, translation of these data into clinical practice has met with 
limited success. Growth factors for clinical use may be either recombinant or 
homologous/autologous.  
Autologous growth factors are harvested from the patient's own platelets, 
yielding an unpredictable combination and concentration of factors, which are 
then applied to the wound. This approach allows treatment with patient-specific 
factors at an apparently physiologic ratio of growth factor concentrations. 
Recombinant molecular biologic means permit the purification of high 
concentrations of individual growth factors. Current Food and Drug 
Administration–approved formulations, as well as those used experimentally, 
deliver concentrations approximately 103 times higher than those observed 
physiologically. 
At present, studies have shown that Epidermal growth factor will enhance the 
wound healing process of diabetic wounds.  
Application of recombinant human EGF in a gel suspension to these wounds 
increases the incidence of total healing, decreases healing time and reduction of 
non-healing ulcers. 
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MATERIALS AND METHODS: 
Place of study:  
All units in general surgery in Government Stanley Medical 
College and Hospital, Chennai-1. 
Study Design: 
Prospective, Non-randomized control trial 
Study Duration: 
July 2014 to June 2015 
Sample Size: 50 
Each Arm 25 
Study tool: 
 Data was collected from all patients who was admitted in 
Government Stanley medical college and patients was included those who 
come under the inclusion criteria 
METHOD 
• For one group of patients, topical application of recombinant human 
epidermal growth factor gel over the wound and wound dressing was  
done twice daily 
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• For other group of patients, topical application of povidone-iodine 
over the wound and wound dressing done twice daily. 
• The study end point was the complete closure of the wound.  
• Failure to heal was arbitrarily defined as incomplete healing after 12 
weeks. 
• Results are tabulated and analyzed. 
INCLUSION CRITERIA: 
o All patients who are diagnosed as type 2 diabetes mellitus 
with a non-healing ulcer 
o Both males and females 
o Age between 35 to 75 years 
o Size of the wound - 5cm to 15cm 
EXCLUSION CRITERIA: 
o Recurrent  ulcers 
o Non-diabetic wounds 
o Malignant ulcers 
Statistical method: 
Descriptive statistics was done for all data and were reported in terms of mean 
values and percentages. Suitable statistical tests of comparison were done. 
Continuous variables were analysed with the unpaired t test. Categorical 
variables were analysed with the Chi-Square Test and Fisher Exact Test. 
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Statistical significance was taken as P < 0.05. The data was analysed using 
SPSS version 16 and Microsoft Excel 2007 
 
INVESTIGATIONS: 
A. Routine investigations: 
• Complete blood count 
• Renal function test 
• Random Blood Sugar 
• Liver function test 
• Serum electrolytes 
• X-ray Chest 
B. Special investigations 
• Pus Culture and sensitivity 
 
• Fasting Blood Sugar 
 
• Post-Prandial Blood sugar 
 
• Doppler scan (if needed) 
 
• X-ray local area (if needed) 
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Initial unhealthy wound  
 
 
 
 
 
 
 
Wound healed with topical application of Human Epidermal growth factor 
 
 
 
 
 
 
 
 
Wound after stump closure 
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Initial unhealthy wound 
 
 
 
 
 
 
 
 
 
Wound healed after topical application of human epidermal growth factor and 
later  stump closure was done 
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Initial wound 
               
                  
Wound healed after topical application of human epidermal growth factor and  
skin graft of the raw area was done 
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            Initial wound 
             
            Wound healed After topical application of human epidermal growth 
factor and  secondary suturing done. 
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RESULTS AND OBSERVATIONS 
This is study consisted of total 50 patients who were admitted with diabetic 
wounds satisfying all inclusion and exclusion criteria, to all units of 
Department of General Surgery in Government Stanley medical college, 
Chennai  during july 2014 to june 2015. 
Total 50 patients with diabetic wounds were studied, each study  group with 25 
patients. 
For first study group of patients, topical application of recombinant human 
epidermal growth factor gel over the wound and wound dressing was done 
twice daily 
For second study group of patients, topical application of povidone-iodine over 
the wound and wound dressing was done twice daily. 
For each patient, wound dressings were done for 12 weeks. 
The findings were analyzed and tabulated. The following observations were 
made: 
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Age Distribution
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71-80 years
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Age 
Distribution 
All % Human 
Epidermal 
Growth 
Factor 
Application 
% Conventional 
Povidone 
Iodine 
Dressing 
% 
≤ 40 years 3 6.00 1 4.00 2 8.00 
41-50 years 9 18.00 4 16.00 5 20.00 
51-60 years 15 30.00 7 28.00 8 32.00 
61-70 
Years 
19 38.00 11 44.00 8 32.00 
71-80 years 4 8.00 2 8.00 2 8.00 
Total 50 100 25 100 25 100 
 
 
 
Age Distribution All Human Epidermal 
Growth Factor 
Application 
Conventional 
Povidone Iodine 
Dressing 
N 50 25 25 
Mean 58.92 60.60 57.24 
SD 10.15 9.62 10.57 
P value Unpaired t Test 0.2457 
 
Majority of the Human Epidermal Growth Factor Application Group patients 
belonged to the 61-70 years age class interval (n=19, 38%) with a mean age of 
60.60 years. In the Conventional Povidone Iodine Dressing group patients, 
majority belonged to the same age class interval (n=8, 32%) with a mean age of 
57.24 years. The association between the intervention groups and age 
distribution is considered to be not statistically significant since p > 0.05 as per 
unpaired t test. 
Gender  
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30, 60%
Gender Distribution
10
15
Male Female
Gender Distribution
Conventional Povidone Iodine Dressing
 
 
Male
Female
10
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Gender 
Distribution 
All % Human 
Epidermal 
Growth 
Factor 
Application 
% Conventional 
Povidone 
Iodine 
Dressing 
% 
Male 30 60.00 15 60.00 15 60.00 
Female 20 40.00 10 40.00 10 40.00 
Total 50 100 25 100 25 100 
P value Fishers Exact Test 0.9999 
 
The Human Epidermal Growth Factor Application group patients equally 
belonged to the male gender class interval (n=15, 50%). In the Conventional 
Povidone Iodine Dressing group patients, majority belonged to the male gender 
class interval (n=15, 50%). The association between the intervention groups 
and gender distribution is considered to be not statistically significant since p > 
0.05 as per fishers exact test. 
  
Duration of Wound Healing
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Duration 
of Wound 
Healing 
All % Human 
Epidermal 
Growth 
Factor 
Application 
% Conventional 
Povidone 
Iodine 
Dressing 
% 
≤ 6 weeks 8 16.00 8 32.00 0 0.00 
7-9 weeks 20 40.00 14 56.00 6 24.00 
10-12 
weeks 
14 28.00 2 8.00 12 48.00 
> 12 
weeks 
8 16.00 1 4.00 7 28.00 
Total 50 100 25 100 25 100 
 
 
Duration of 
Wound Healing 
All Human Epidermal 
Growth Factor 
Application 
Conventional Povidone 
Iodine Dressing 
N 50 25 25 
Mean 9.30 7.72 10.88 
SD 2.37 1.88 1.64 
P value Unpaired t Test 0.0001 
 
 
 
 
 
 
 
 
 
Final Status of Wound
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31, 62%
8, 16%
Final Status of Wound
Skin Graft
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Secondary Suturing
Non Healing
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1
7
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Final Status of 
Wound 
All % Human 
Epidermal 
Growth 
Factor 
Application 
% Conventional 
Povidone 
Iodine 
Dressing 
% 
Skin Graft 31 62.00 17 68.00 14 56.00 
Stump Closure 6 12.00 3 12.00 3 12.00 
Secondary 
Suturing 
5 10.00 4 16.00 1 4.00 
Non Healing 8 16.00 1 4.00 7 28.00 
Total 50 100 25 100 25 100 
P value Fishers Exact Test 0.0191 
 
 
KM Analysis 
 
 
log-rank test; z = 0.98, p = 0.033 
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If you are in Epidermal Growth Factor Application Group, your probability of 
wound healing in 7 weeks is 100%.  
 If you are in Conventional Povidone Iodine Dressing  Group , your probability 
of wound healing at the same time is slightly more than 76%.  
It is statistically significant with a p-value of 0.033 as per log-rank test 
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DISCUSSION 
Wound and wound healing is an important discussion topic for centuries. 
Wound healing is hindered by many factor. One of the most important 
hindrance to wound healing or that impedes the steps of wound healing is 
associated Type 2 Diabetes Mellitus. Major factor in diabetes that delays or 
hinder with wound healing are obesity, uncontrolled hyperglycemia, renal 
compromise, and insulin resistance . Uncontrolled diabetes results in reduced 
inflammation, angiogenesis, and collagen synthesis.  
Additionally, the large- and small-vessel disease that is the hallmark of 
advanced diabetes contributes to local hypoxemia.  
Defects in granulocyte function, capillary ingrowth, and fibroblast proliferation 
all have been described in diabetes.  
Obesity, insulin resistance, hyperglycemia, and diabetic renal failure contribute 
significantly and independently to the impaired wound healing observed in 
diabetics.  
The diabetic wound appears to be lacking in sufficient growth factor levels, 
which signal normal healing. It remains unclear whether decreased collagen 
synthesis or an increased breakdown due to an abnormally high proteolytic 
wound environment is responsible. 
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Careful correction of blood sugar levels improves the outcome of wounds in 
diabetic patients. Increasing the inspired oxygen tension, judicious use of 
antibiotics, and correction of other coexisting metabolic abnormalities all can 
result in improved wound healing. 
Diabetes is still one of the major cause for limb amputations mainly in lower 
limb. 
Increased level of glucose in tissues or uncontrolled level of glucose in tissues 
precipitates infection, and lead to vascular compromise which in turn results in 
a non-healing wound or even may lead to amputation if it is in extremities, 
mainly in lower extremities. 
Human epidermal growth factor stimulates cell growth, differentiation, and 
proliferation by binding to it EGFR receptor. 
In case of T2 DM previous studies has shown that topical application of 
epidermal growth factor is enhancing the wound healing than other 
conventional methods.  
In our study total number of patients included was 50, each arm 25,that means, 
25 patients were treated with topical application of human epidermal growth 
factor and other group of 25 was treated with application of conventional 
povidine iodine dressing. Also intermittent wound debridement was done to 
remove slough according to the need of the wound. 
This study was conducted from July 2014 to June 2015. 
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This study has undertaken to know whether the topical application of human 
epidermal growth factor gel over diabetic wounds will enhance faster wound 
healing than conventional povidine iodine dressing or to say in any ways 
human epidermal growth factor is superior to conventional dressings. 
Based on our study, following observations were made: 
AGE 
We conducted study with total 50 patients, each arm 25. 
In case of epidermal growth factor more patients were in age group of 60–70 
years, that is around 44%, that is, mean age of 60.6 years 
In case of povidine iodine dressing more patients were in two groups 50-60 and 
60-70 years, that is around 32% with a mean age of 57.24 years 
The association between the intervention groups and age distribution is 
considered to be not statistically significant since p > 0.05 as per unpaired t 
test. 
SEX 
In the study, of total patients 60% were male and 40% were females. The 
association between the intervention groups and gender distribution is 
considered to be not statistically significant since p > 0.05 as per fishers exact 
test. 
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DURATION OF WOUND HEALING 
In our study, we found that in patients we used human epidermal growth factor, 
16% healed within 6 weeks of time, another 56% healed by 9 weeks of time, 
8% healed by 12 weeks and only 4% went for non healing wound. 
In case  of patients we used povidine-iodine dressing we found that no patients 
healed by 6 weeks of time, 24% patients healed by 9 weeks of time, another 
48% healed by 12 weeks time and 28% patients did not heal, and went for non-
healing wound. 
The decreased mean duration of wound healing in Human Epidermal Growth 
Factor Application Group compared to the Conventional Povidone Iodine 
Dressing Group is statistically significant as the p value is 0.0001 as per 
unpaired t- test indicating a true difference among study groups.  
The mean duration of wound healing was meaningfully less in Human 
Epidermal Growth Factor Application Group compared to the Conventional 
Povidone Iodine Dressing  Group by 3.16 weeks. This significant difference of  
29% decrease in mean duration of wound healing in Human Epidermal Growth 
Factor Application Group compared to the Conventional Povidone Iodine 
Dressing Group is true and has not occurred by chance 
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FINAL STATUS OF WOUND 
In our study we found that, in case of  patients we did dressings with human 
epidermal growth factor   68% patients wound resulted in skin graft, 12 % 
patients went for stump closure, 16% patients went for secondary suturing. In 
4% patients wounds were non-healing. 
In case of patients we did dressing with povidine iodine, 56% patients wound 
resulted in skin graft, another 12% patients wound resulted in stump closure, 
4% patients wound went for secondary suturing finally. In this study group 
around 28% patients with diabetic wounds resulted as non-healing ulcer. 
So our study strongly proves that with use of epidermal growth factor in 
diabetic wounds significantly reduces the incidence of non-healing ulcer as 
compared to povidine-iodine dressing. 
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    SUMMARY 
 The study was done with 50 patients in all surgical units of department of 
general surgery, Govt. Stanley medical college & hospital, Chennai from july 
2014 to june 2015. The purpose of the study was to compare human epidermal 
growth factor dressing with povidine iodine dressing in diabetic wounds and to 
prove whether topical application of human epidermal growth factor enhances 
wound healing better than conventional povidine iodine dressing. 
  All patients male and female from age 35 up to 75 years undergoing 
treatment for diabetic wounds were considered in the study 
The observations of study summarized below: 
• Patients we used topical application of human epidermal growth factor, 
healing of wounds on an average took about 7.72 weeks and in case of 
povidine-iodine dressing it took about 10.88 weeks to heal the wound. 
• The mean duration of wound healing was meaningfully less in Human 
Epidermal Growth Factor Application Group compared to the 
Conventional Povidone Iodine Dressing  Group by 3.16 weeks. This 
significant difference of  29% decrease in mean duration of wound 
healing in Human Epidermal Growth Factor Application Group 
compared to the Conventional Povidone Iodine Dressing Group is true 
and has not occurred by chance 
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• In case of final status of the wound we found that, in case of  patients we 
treated with human epidermal growth factor 68% patients wound 
resulted in skin graft, 12 % patients went for stump closure, 16% 
patients went for secondary suturing and  4% patients wounds were non-
healing. 
• In case of patients we treated with povidine iodine, 56% patients wound 
resulted in skin graft, another 12% patients wound resulted in stump 
closure, 4% patients wound went for secondary suturing finally. In this 
study group around 28% patients with diabetic wounds resulted as non-
healing ulcer. 
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CONCLUSION 
 
 The results of the study concludes that the topical application of human 
epidermal growth factor enhances wound healing significantly and is 
better than conventional povidine iodine dressing. 
 Results of the study also concludes that the topical application of human 
epidermal growth factor causes significant reduction in number of non-
healing ulcers. 
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ANNEXURES 
PROFORMA 
NAME:        AGE/SEX: 
OCCUPATION:       IP NO: 
SL.NO:        ADDRESS 
WITH CONTACT NO: 
DATE OF ADMISSION:      
DATE OF DISCHARGE: 
CHIEF COMPLAINT: 
 
HISTORY OF PRESENTING ILLNESS: 
 
PAST HISTORY: 
 
PERSONAL HISTORY: 
 
OCCUPATIONAL HISTORY: 
 
FAMILY HISTORY: 
 
TREATMENT HISTORY: 
 
GENERAL EXAMINATION: 
 
LOCAL EXAMINATION: 
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CLINICAL DIAGNOSIS: 
 
INVESTIGATIONS 
A. Routine investigations: 
• Complete blood count 
• Renal function test 
• Random blood sugar 
• Liver function test   
• Serum electrolytes  
• X-ray chest pa view 
B. Special investigations: 
• Pus culture and sensitivity 
• Fasting blood sugar 
• Post prandial blood sugar 
• Doppler scan (if needed) 
• X-ray local area (if needed) 
 
TYPE OF DRESSING 
(human epidermal growth factor/povidine iodine) : 
 
DURATION OF WOUND HEALING: 
 
FINAL STATUS OF WOUND: 
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GOVT.STANLEY MEDICAL COLLEGE, CHENNAI- 600 001 
INFORMED CONSENT 
 
DISSERTATION TOPIC: “A COMPARATIVE STUDY ON WOUND 
HEALING WITH TOPICAL APPLICATION OF HUMAN 
EPIDERMAL GROWTH FACTOR VERSES  APPLICATION OF 
POVIDONE-IODINE IN DIABETIC WOUNDS”. 
 
PLACE OF STUDY: GOVT. STANLEY MEDICAL COLLEGE, CHENNAI 
 
NAME AND ADDRESS OF PATIENT: 
 
 
I, _____________________ have been informed about the details of the study 
in my own language. 
I have completely understood the details of the study. 
I am aware of the possible risks and benefits, while taking part in the study. 
I understand that I can withdraw from the study at any point of time and even 
then, I will continue to receive the medical treatment as usual. 
I understand that I will not get any payment for taking part in this study. 
I will not object if the results of this study are getting published in any medical 
journal, provided my personal identity is not revealed. 
I know what I am supposed to do by taking part in this study and I assure that I 
would extend my full co-operation for this study. 
 
Name and Address of the Volunteer:  
 
Signature/Thumb impression of the Volunteer 
 
Date: 
Witnesses: 
(Signature, Name & Address) 
 
Date: 
Name and signature of investigator: 
 
Date: 
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இuni0BA8_uni0BCDத மuni0BB0_uni0BC1uni0BA4_uni0BCDuni0BA4_uni0BC1வ ஆuni0BAF_uni0BCDவிuni0BA9_uni0BCD விவரuni0B99_uni0BCDகuni0BB3_uni0BCD எனuni0B95_uni0BCDuni0B95_uni0BC1 
விளuni0B95_uni0BCDகuni0BAA_uni0BCDபuni0B9F_uni0BCDடuni0BA4_uni0BC1. எuni0BA9_uni0BCDuni0BA9_uni0BC1ைடய சuni0BA8_uni0BCDேதகuni0B99_uni0BCDகைளuni0B95_uni0BCD 
ேகuni0B9F_uni0BCDகuni0BB5_uni0BC1uni0BAE_uni0BCD, அதuni0BB1_uni0BCDகான தuni0B95_uni0BC1uni0BA8_uni0BCDத விளuni0B95_uni0BCDகuni0B99_uni0BCDகைளuni0BAA_uni0BCD 
ெபறuni0BB5_uni0BC1uni0BAE_uni0BCD வாuni0BAF_uni0BCDuni0BAA_uni0BCDபளிuni0B95_uni0BCDகuni0BAA_uni0BCDபuni0B9F_uni0BCDடuni0BA4_uni0BC1. 
நாuni0BA9_uni0BCD இuni0BB5_uni0BCDவாuni0BAF_uni0BCDவிuni0BB2_uni0BCD தuni0BA9_uni0BCDனிuni0B9A_uni0BCDைசயாகuni0BA4_uni0BCDதாuni0BA9_uni0BCD 
பuni0B99_uni0BCDேகuni0BB1_uni0BCDகிேறuni0BA9_uni0BCD. எuni0BA8_uni0BCDதகாரணuni0BA4_uni0BCDதினாuni0BB2_uni0BC1uni0BAE_uni0BCD, எuni0BA8_uni0BCDத 
கuni0B9F_uni0BCDடuni0BA4_uni0BCDதிuni0BB2_uni0BC1uni0BAE_uni0BCD, எuni0BA8_uni0BCDதசuni0B9F_uni0BCDடசிuni0B95_uni0BCDகuni0BB2_uni0BC1uni0BAE_uni0BCD இuni0BA9_uni0BCDறி இuni0BA8_uni0BCDத 
ஆuni0BAF_uni0BCDவிலிuni0BB0_uni0BC1uni0BA8_uni0BCDuni0BA4_uni0BC1 விலகிuni0B95_uni0BCD ெகாuni0BB3_uni0BCDளலாuni0BAE_uni0BCD எuni0BA9_uni0BCDuni0BB1_uni0BC1uni0BAE_uni0BCD அறிuni0BA8_uni0BCDuni0BA4_uni0BC1 
ெகாuni0BA3_uni0BCDேடuni0BA9_uni0BCD. 
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நாuni0BA9_uni0BCD ஆuni0BAF_uni0BCDவிலிuni0BB0_uni0BC1uni0BA8_uni0BCDuni0BA4_uni0BC1 விலகிuni0B95_uni0BCDெகாuni0BA3_uni0BCDடாuni0BB2_uni0BC1uni0BAE_uni0BCD ஆuni0BAF_uni0BCDவாள! 
எuni0BA9_uni0BCDuni0BA9_uni0BC1ைடய மuni0BB0_uni0BC1uni0BA4_uni0BCDuni0BA4_uni0BC1வ அறிuni0B95_uni0BCDைககைளuni0BAA_uni0BCD பா!uni0BAA_uni0BCDபதuni0BB1_uni0BCDேகா 
அuni0BB2_uni0BCDலuni0BA4_uni0BC1 உபேயாகிuni0B95_uni0BCDகேவா எuni0BA9_uni0BCD அuni0BA9_uni0BC1மதி 
ேதைவயிuni0BB2_uni0BCDைல எனuni0BB5_uni0BC1uni0BAE_uni0BCD அறிuni0BA8_uni0BCDuni0BA4_uni0BC1ெகாuni0BA3_uni0BCDேடuni0BA9_uni0BCD. 
எuni0BA9_uni0BCDைனuni0BAA_uni0BCD பuni0BB1_uni0BCDறிய தகவuni0BB2_uni0BCDகuni0BB3_uni0BCD இரகசியமாகuni0BAA_uni0BCD 
பாuni0BA4_uni0BC1காuni0B95_uni0BCDகuni0BAA_uni0BCDபuni0B9F_uni0BC1uni0BAE_uni0BCD எuni0BA9_uni0BCDபைதuni0BAF_uni0BC1uni0BAE_uni0BCD அறிேவuni0BA9_uni0BCD. 
இuni0BA8_uni0BCDத ஆuni0BAF_uni0BCDவிuni0BA9_uni0BCD uni0BAE_uni0BC2லuni0BAE_uni0BCD கிைடuni0B95_uni0BCDuni0B95_uni0BC1uni0BAE_uni0BCD தகவuni0BB2_uni0BCDகைளuni0BAF_uni0BC1uni0BAE_uni0BCD 
பேசாதைன uni0BAE_uni0BC1uni0B9F_uni0BBFuni0BB5_uni0BC1கைளuni0BAF_uni0BC1uni0BAE_uni0BCD ஆuni0BAF_uni0BCDவாள! அவ! 
விuni0BB0_uni0BC1uni0BAA_uni0BCDபuni0BA4_uni0BCDதிuni0BB1_uni0BCDேகuni0BB1_uni0BCDப எuni0BB5_uni0BCDவிதமாகuni0BAA_uni0BCD 
பயuni0BA9_uni0BCDபuni0B9F_uni0BC1uni0BA4_uni0BCDதிuni0B95_uni0BCDெகாuni0BB3_uni0BCDளuni0BB5_uni0BC1uni0BAE_uni0BCD, அதைன பிரuni0B9A_uni0BC1uni0B95_uni0BCDகuni0BB5_uni0BC1uni0BAE_uni0BCD 
uni0BAE_uni0BC1uni0BB4_uni0BC1மனuni0BA4_uni0BC1டuni0BA9_uni0BCD சuni0BAE_uni0BCDமதிuni0B95_uni0BCDகிேறuni0BA9_uni0BCD. 
இuni0BA8_uni0BCDத ஆuni0BAF_uni0BCDவிuni0BB2_uni0BCD பuni0B99_uni0BCDuni0B95_uni0BC1 ெகாuni0BB3_uni0BCDள ஒuni0BAA_uni0BCDuni0BAA_uni0BC1uni0B95_uni0BCDெகாuni0BB3_uni0BCDகிேறuni0BA9_uni0BCD. 
எனuni0B95_uni0BCDuni0B95_uni0BC1 ெகாuni0B9F_uni0BC1uni0B95_uni0BCDகuni0BAA_uni0BCDபuni0B9F_uni0BCDட அறிuni0BB5_uni0BC1ைரகளிuni0BA9_uni0BCDபuni0B9F_uni0BBF 
நடuni0BA8_uni0BCDuni0BA4_uni0BC1ெகாuni0BB3_uni0BCDவuni0BA4_uni0BC1டuni0BA9_uni0BCD ஆuni0BAF_uni0BCDவாளuni0BB0_uni0BC1uni0B95_uni0BCDuni0B95_uni0BC1 உuni0BA3_uni0BCDைமuni0BAF_uni0BC1டuni0BA9_uni0BCD 
இuni0BB0_uni0BC1uni0BAA_uni0BCDேபuni0BA9_uni0BCD எuni0BA9_uni0BCDuni0BB1_uni0BC1uni0BAE_uni0BCD உuni0BB1_uni0BC1தியளிuni0B95_uni0BCDகிேறuni0BA9_uni0BCD. எuni0BA9_uni0BCD உடuni0BB2_uni0BCDநலuni0BAE_uni0BCD 
பாதிuni0B95_uni0BCDகuni0BAA_uni0BCDபuni0B9F_uni0BCDடாேலா அuni0BB2_uni0BCDலuni0BA4_uni0BC1வழuni0B95_uni0BCDகuni0BA4_uni0BCDதிuni0BB1_uni0BCDuni0B95_uni0BC1 மாறான 
ேநாuni0BAF_uni0BCDuni0B95_uni0BCDuni0B95_uni0BC1றிெதuni0BA9_uni0BCDபuni0B9F_uni0BCDடாேலா உடேன அைத 
ெதவிuni0BAA_uni0BCDேபuni0BA9_uni0BCD என உuni0BB1_uni0BC1திuni0B95_uni0BC2uni0BB1_uni0BC1கிேறuni0BA9_uni0BCD. 
இuni0BA8_uni0BCDத ஆuni0BAF_uni0BCDவிuni0BB2_uni0BCD எனuni0B95_uni0BCDuni0B95_uni0BC1 எuni0BB5_uni0BCDவிதமான 
பேசாதைனகைளuni0BAF_uni0BC1uni0BAE_uni0BCD, சிகிuni0B9A_uni0BCDைசகைளuni0BAF_uni0BC1uni0BAE_uni0BCD ேமuni0BB1_uni0BCDெகாuni0BB3_uni0BCDள 
நாuni0BA9_uni0BCD uni0BAE_uni0BC1uni0BB4_uni0BC1மனuni0BA4_uni0BC1டuni0BA9_uni0BCD சuni0BAE_uni0BCDமதிuni0B95_uni0BCDகிேறuni0BA9_uni0BCD. 
இuni0BAA_uni0BCDபuni0B9F_uni0BBFuni0B95_uni0BCDuni0B95_uni0BC1 
ேநாயளியிuni0BA9_uni0BCDைகெயாuni0BAA_uni0BCDபuni0BAE_uni0BCD                                      
ஆuni0BAF_uni0BCDவாள!ைகெயாuni0BAA_uni0BCDபuni0BAE_uni0BCD 
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ெபய!                                                         
(மuni0BB0_uni0BC1.uni0BAE_uni0BCDuni0BB0_uni0BC1uni0BA4_uni0BC1uni0BB2_uni0BCD மாதிuni0BAF_uni0BC1.)  
 
 
 
நழிuni0BB5_uni0BC1ேநாயாளிகளிuni0BA9_uni0BCD காயuni0BA4_uni0BCDைத ஆuni0BB1_uni0BCDuni0BB1_uni0BC1வதிuni0BB2_uni0BCD 
ேமuni0BA9_uni0BCDைமயானuni0BA4_uni0BC1 ேமuni0BB1_uni0BCDuni0BAA_uni0BC2uni0B9A_uni0BCDuni0B9A_uni0BC1 ேமuni0BB1_uni0BCDேறாuni0BB2_uni0BC1uni0B95_uni0BCDuni0B95_uni0BC1ய 
வள!uni0B9A_uni0BCDசிuni0B95_uni0BCDகாரணியா அuni0BB2_uni0BCDலuni0BA4_uni0BC1         
அேயாuni0B9F_uni0BBFuni0BA9_uni0BCDதாuni0BA4_uni0BC1 ௧uni0B9F_uni0BCDடா என xuni0BAA_uni0BCDபிuni0B9F_uni0BCDuni0B9F_uni0BC1uni0BAA_uni0BCDபா!uni0B95_uni0BCDuni0B95_uni0BC1uni0BAE_uni0BCD 
aaggnnmvvbbMa;T 
 
ஆuni0BAF_uni0BCDவாள!:மuni0BB0_uni0BC1.uni0BAE_uni0BCDuni0BB0_uni0BC1uni0BA4_uni0BC1uni0BB2_uni0BCD மாதிuni0BAF_uni0BC1, 
uni0BAE_uni0BC1uni0BA4_uni0BC1நிைலபuni0B9F_uni0BCDடேமuni0BB1_uni0BCDபuni0B9F_uni0BBFuni0BAA_uni0BCDuni0BAA_uni0BC1மாணவ!,  
அuni0BB1_uni0BC1ைவசிகிuni0B9A_uni0BCDைசபuni0B9F_uni0BCDடபuni0B9F_uni0BBFuni0BAA_uni0BCDuni0BAA_uni0BC1. 
 
வழிகாuni0B9F_uni0BCDuni0B9F_uni0BBF:ேபராசிய!மuni0BB0_uni0BC1.விuni0BB7_uni0BCDவநாதuni0BA9_uni0BCD,  
அuni0BB1_uni0BC1ைவசிகிuni0B9A_uni0BCDைசேபராசிய!, 
அரuni0B9A_uni0BC1uni0BB8_uni0BCDடாuni0BA9_uni0BCDலிமuni0BB0_uni0BC1uni0BA4_uni0BCDuni0BA4_uni0BC1வமைன. 
பuni0B99_uni0BCDேகuni0BB1_uni0BCDபாளuni0BA9_uni0BCDதகவuni0BB2_uni0BCDபuni0B9F_uni0BBFவuni0BAE_uni0BCD 
நuni0B99_uni0BCDகuni0BB3_uni0BCD இuni0BA8_uni0BCDத ஆuni0BAF_uni0BCDவிuni0BB2_uni0BCD பuni0B99_uni0BCDேகuni0BB1_uni0BCDக 
அைழuni0B95_uni0BCDகuni0BAA_uni0BCDபuni0B9F_uni0BC1கிற!கuni0BB3_uni0BCD. இuni0BA8_uni0BCDத ஆuni0BAF_uni0BCDவிuni0BB2_uni0BCD பuni0B99_uni0BCDேகuni0BB1_uni0BCDuni0B95_uni0BC1uni0BAE_uni0BCD 
uni0BAE_uni0BC1uni0BA9_uni0BCD, இதuni0BA9_uni0BCD ேநாuni0B95_uni0BCDகuni0BA4_uni0BCDைதuni0BAF_uni0BC1uni0BAE_uni0BCD, uni0BAE_uni0BC1ைறகைளuni0BAF_uni0BC1uni0BAE_uni0BCD, 
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இதனாuni0BB2_uni0BCD ஏuni0BB1_uni0BCDபuni0B9F_uni0BC1uni0BAE_uni0BCD பிuni0BA9_uni0BCD விைளuni0BB5_uni0BC1கைளuni0BAF_uni0BC1uni0BAE_uni0BCD நuni0B99_uni0BCDகuni0BB3_uni0BCD 
அறிuni0BA8_uni0BCDuni0BA4_uni0BC1ெகாuni0BB3_uni0BCDள ஆuni0BAF_uni0BCDவாள! அளிuni0B95_uni0BCDuni0B95_uni0BC1uni0BAE_uni0BCD தகவuni0BB2_uni0BCD: 
நழிuni0BB5_uni0BC1 ேநாயாளிகuni0BB3_uni0BCD இuni0BA8_uni0BCDத ஆuni0BAF_uni0BCDவிuni0BB2_uni0BCD 
ேச!uni0BA4_uni0BCDuni0BA4_uni0BC1uni0B95_uni0BCDெகாuni0BB3_uni0BCDளuni0BAA_uni0BCDபuni0B9F_uni0BC1வா!கuni0BB3_uni0BCD. உuni0B99_uni0BCDகuni0BB3_uni0BCD ேநாயிuni0BA9_uni0BCD 
வரலாuni0BB1_uni0BC1uni0BAE_uni0BCD, உuni0B99_uni0BCDகளிuni0BA9_uni0BCD uni0BAE_uni0BC1uni0BB4_uni0BC1 உடuni0BB2_uni0BCD பேசாதைனuni0BAF_uni0BC1uni0BAE_uni0BCD 
ெதளிவாகuni0BB5_uni0BC1uni0BAE_uni0BCD விவாகuni0BB5_uni0BC1uni0BAE_uni0BCD பதிuni0BB5_uni0BC1 ெசuni0BAF_uni0BCDயuni0BAA_uni0BCDபuni0B9F_uni0BC1uni0BAE_uni0BCD. 
உuni0B99_uni0BCDகளிuni0BA9_uni0BCD காயuni0BAE_uni0BCD ேம!uni0B95_uni0BCDuni0B95_uni0BC1ய இuni0BB0_uni0BC1 uni0BAE_uni0BC1ைர௧ளிuni0BB2_uni0BCD 
ஏேதuni0BA9_uni0BC1uni0BAE_uni0BCD ஒ௫ uni0BAE_uni0BC1ைறயிuni0BB2_uni0BCD ஆuni0BB1_uni0BCDறuni0BAA_uni0BCDபuni0B9F_uni0BC1uni0BAE_uni0BCD. 
இuni0BA8_uni0BCDத ஆuni0BAF_uni0BCDவிuni0BA9_uni0BCD uni0BAE_uni0BC1uni0B9F_uni0BBFuni0BB5_uni0BC1கuni0BB3_uni0BCD மuni0BB0_uni0BC1uni0BA4_uni0BCDuni0BA4_uni0BC1வ 
காரணuni0B99_uni0BCDகuni0BB3_uni0BC1uni0B95_uni0BCDகாகuni0BB5_uni0BC1uni0BAE_uni0BCD, மuni0BB0_uni0BC1uni0BA4_uni0BCDuni0BA4_uni0BC1வ கuni0BB2_uni0BCDவிuni0B95_uni0BCDகாகuni0BB5_uni0BC1uni0BAE_uni0BCD 
பயuni0BA9_uni0BCDபuni0B9F_uni0BC1uni0BA4_uni0BCDதuni0BAA_uni0BCDபuni0B9F_uni0BC1uni0BAE_uni0BCD. இuni0BA8_uni0BCDத ஆuni0BAF_uni0BCDuni0BB5_uni0BC1 பuni0BB1_uni0BCDறிய 
சuni0BA8_uni0BCDேதகuni0B99_uni0BCDகuni0BB3_uni0BC1uni0B95_uni0BCDuni0B95_uni0BC1 உய uni0BAE_uni0BC1ைறயிuni0BB2_uni0BCD 
விளuni0B95_uni0BCDகமளிuni0B95_uni0BCDகuni0BAA_uni0BCDபuni0B9F_uni0BC1uni0BAE_uni0BCD. தuni0B99_uni0BCDகைளuni0BAA_uni0BCD பuni0BB1_uni0BCDறிய தகவuni0BB2_uni0BCDகuni0BB3_uni0BCD 
இரகசியமாக பாuni0BA4_uni0BC1காuni0B95_uni0BCDகuni0BAA_uni0BCDபuni0B9F_uni0BC1uni0BAE_uni0BCD. 
இuni0BA8_uni0BCDத ஆuni0BAF_uni0BCDவிuni0BB2_uni0BCD இuni0BB0_uni0BC1uni0BA8_uni0BCDuni0BA4_uni0BC1 எuni0BAA_uni0BCDேபாuni0BA4_uni0BC1 ேவuni0BA3_uni0BCDuni0B9F_uni0BC1மானாuni0BB2_uni0BC1uni0BAE_uni0BCD 
தாuni0B99_uni0BCDகuni0BB3_uni0BCD எuni0BB5_uni0BCDவித uni0BAE_uni0BC1uni0BA9_uni0BCDனறிவிuni0BAA_uni0BCDபிuni0BA9_uni0BCDறிuni0BAF_uni0BC1uni0BAE_uni0BCD, எuni0BB5_uni0BCDவித 
சuni0B9F_uni0BCDடசிuni0B95_uni0BCDகuni0BB2_uni0BC1uni0BAE_uni0BCD இuni0BA9_uni0BCDறி விலகிuni0B95_uni0BCDெகாuni0BB3_uni0BCDளலாuni0BAE_uni0BCD. 
இuni0BA8_uni0BCDத ஆuni0BAF_uni0BCDவிuni0BB2_uni0BCD பuni0B99_uni0BCDேகuni0BB1_uni0BCDuni0B95_uni0BC1மாuni0BB1_uni0BC1 ேகuni0B9F_uni0BCDuni0B9F_uni0BC1uni0B95_uni0BCDெகாuni0BB3_uni0BCDகிேறuni0BA9_uni0BCD. 
நuni0BA9_uni0BCDறி, 
 
ஆuni0BAF_uni0BCDவாள!ைகெயாuni0BAA_uni0BCDபuni0BAE_uni0BCD                                 
ேநாயாளியிuni0BA9_uni0BCDைகெயாuni0BAA_uni0BCDபuni0BAE_uni0BCD   (மuni0BB0_uni0BC1. uni0BAE_uni0BCDuni0BB0_uni0BC1uni0BA4_uni0BC1uni0BB2_uni0BCD மாதிuni0BAF_uni0BC1)                                 
(ெபய!:                    ) 
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MASTER CHART 
Sl. no age sex IP no. Diagnosis 
time limit for 
study 
DURATION OF WOUND HEALING 
WITH EPIDERMAL GROWTH FACTOR 
FINAL STATUS OF WOUND 
1 
56 
F 1541650 DIABETIC WOUND 12 WEEKS 6 WEEKS SKIN GRAFT 
2 58 F 1540539 DIABETIC WOUND 12 WEEKS 8 WEEKS SKIN GRAFT 
3 69 F 1541250 DIABETIC WOUND 12 WEEKS 7 WEEKS SKIN GRAFT 
4 68 M 1541351 DIABETIC WOUND 12 WEEKS 11 WEEKS STUMP CLOSURE 
5 66 M 1541127 DIABETIC WOUND 12 WEEKS 8 WEEKS SKIN GRAFT 
6 48 M 1540589 DIABETIC WOUND 12 WEEKS 6 WEEKS SECONDARY SUTURING 
7 69 M 1554531 DIABETIC WOUND 12 WEEKS 9 WEEKS SKIN GRAFT 
8 73 F 1552948 DIABETIC WOUND 12 WEEKS 10 WEEKS SKIN GRAFT 
9 70 M 1544596 DIABETIC WOUND 12 WEEKS > 12 WEEKS NON HEALING 
10 67 M 1544549 DIABETIC WOUND 12 WEEKS 8 WEEKS STUMP CLOSURE 
11 66 M 1554075 DIABETIC WOUND 12 WEEKS 7 WEEKS SKIN GRAFT 
12 57 F 1554164 DIABETIC WOUND 12 WEEKS 6 WEEKS SKIN GRAFT 
13 49 F 1535450 DIABETIC WOUND 12 WEEKS 6 WEEKS SKIN GRAFT 
14 39 M 1564653 DIABETIC WOUND 12 WEEKS 5 WEEKS SECONDARY SUTURING 
15 73 F 1534009 DIABETIC WOUND 12 WEEKS 9WEEKS SKIN GRAFT 
16 56 F 1554611 DIABETIC WOUND 12 WEEKS 6WEEKS SKIN GRAFT 
17 47 F 1515550 DIABETIC WOUND 12 WEEKS 6WEEKS SKIN GRAFT 
18 54 M 1544750 DIABETIC WOUND 12 WEEKS 7 WEEKS SKIN GRAFT 
19 70 M 1551603 DIABETIC WOUND 12 WEEKS 9 WEEKS SKIN GRAFT 
20 67 M 1554128 DIABETIC WOUND 12 WEEKS 9 WEEKS STUMP CLOSURE 
21 69 M 1545466 DIABETIC WOUND 12 WEEKS 8 WEEKS SKIN GRAFT 
22 61 M 1554715 DIABETIC WOUND 12 WEEKS 8 WEEKS SKIN GRAFT 
23 59 M 1545322 DIABETIC WOUND 12 WEEKS 8 WEEKS SECONDARY SUTURING 
24 60 F 1553172 DIABETIC WOUND 12 WEEKS 8 WEEKS SKIN GRAFT 
25 44 M 1558614 DIABETIC WOUND 12 WEEKS 5 WEEKS SECONDARY SUTURING 
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Sl. no age Sex IP no. diagnosis time limit for study 
DURATION OF WOUND HEALING WITH 
POVIDINE IODINE DRESSSING 
FINAL STATUS OF WOUND 
1 46 M 1512949 DIABETIC WOUND 12 WEEKS 10 WEEKS SKIN GRAFT 
2 55 F 1554114 DIABETIC WOUND 12 WEEKS 9 WEEKS STUMP CLOSURE 
3 74 F 1544844 DIABETIC WOUND 12 WEEKS > 12 WEEKS NON HEALING 
4 70 F 1543561 DIABETIC WOUND 12 WEEKS 11 WEEKS STUMP CLOSURE 
5 68 M 1541688 DIABETIC WOUND 12 WEEKS >12 WEEKS NON HEALING 
6 47 M 1542701 DIABETIC WOUND 12 WEEKS 10 WEEKS SKIN GRAFT 
7 54 M 1544321 DIABETIC WOUND 12 WEEKS 9 WEEKS SKIN GRAFT 
8 60 M 1544211 DIABETIC WOUND 12 WEEKS 12 WEEKS SKIN GRAFT 
9 59 M 1543765 DIABETIC WOUND 12 WEEKS >12 WEEKS NON HEALING 
10 38 M 1542899 DIABETIC WOUND 12 WEEKS 10 WEEKS SKIN GRAFT 
11 66 F 1547544 DIABETIC WOUND 12 WEEKS 10 WEEKS SKIN GRAFT 
12 68 F 1537345 DIABETIC WOUND 12 WEEKS > 12 WEEKS NON HEALING 
13 53 M 1549476 DIABETIC WOUND 12 WEEKS 11 WEEKS SKIN GRAFT 
14 63 M 1533675 DIABETIC WOUND 12 WEEKS 11 WEEKS SKIN GRAFT 
15 44 M 1537109 DIABETIC WOUND 12 WEEKS 9 WEEKS SKIN GRAFT 
16 71 F 1530637 DIABETIC WOUND 12 WEEKS >12 WEEKS NON HEALING 
17 59 F 1540013 DIABETIC WOUND 12 WEEKS 10 WEEKS SKIN GRAFT 
18 65 M 1538909 DIABETIC WOUND 12 WEEKS 12 WEEKS SECONDARY SUTURING 
19 52 M 1547701 DIABETIC WOUND 12 WEEKS 9 WEEKS SKIN GRAFT 
20 47 F 1549001 DIABETIC WOUND 12 WEEKS 9 WEEKS SKIN GRAFT 
21 40 M 1537890 DIABETIC WOUND 12 WEEKS 8 WEEKS STUMPCLOSURE 
22 44 M 1546780 DIABETIC WOUND 12 WEEKS 10 WEEKS SKIN GRAFT 
23 54 F 1531400 DIABETIC WOUND 12 WEEKS 11 WEEKS SKIN GRAFT 
24 70 M 1541234 DIABETIC WOUND 12 WEEKS > 12 WEEKS NON HEALING 
25 64 F 1534390 DIABETIC WOUND 12 WEEKS >12 WEEKS NON HEALING 
 
